RECBIO-B (02179) Announces Interim Results: Loss Narrows 37.82% to Approximately RMB 212 Million

Stock News08-19

RECBIO-B (02179) has released its interim results for the 2026 fiscal year, reporting a substantial reduction in its net loss attributable to shareholders. The company posted a loss of approximately RMB 212 million for the period, marking a 37.82% improvement compared to the same period last year.

The company's revenue for the period stood at roughly RMB 47,000, a significant decline of 99.57% year-over-year. This sharp drop is primarily attributed to the absence of revenue from intellectual property licensing, which had contributed RMB 10.8 million in the prior corresponding period. According to the company's announcement, while similar licensing arrangements are currently in progress, they have not yet met the criteria for revenue recognition under applicable accounting standards.

On a per-share basis, the company recorded a loss of RMB 0.34 for the reporting period. The narrower loss reflects ongoing cost management and operational adjustments, even as the company continues to advance its pipeline and licensing initiatives.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment